The Asia Pacific Neuromodulation Market is expected to witness market growth of 6.6% CAGR during the forecast period (2022-2028).
Disorders of the brain, as well as the nerves that run all through the human body and the spinal cord, are referred to as neurological disorders. Some of the most common neurological ailments are acute spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ataxia, Bell's palsy, brain tumors, cerebral aneurysms, epilepsy, and seizures. Memory loss, poor mental capacity, lack of coordination, and chronic or abrupt onset of a headache are all signs of biochemical, structural, or electrical problems in the brain, spinal cord, or other nerves. Neuromodulation technology makes use of devices that stimulate or modulate brain activity to cause a change in the nervous system. When standard treatments have failed to elicit the desired reaction, they are utilized.
The rising prevalence of chronic conditions, as well as the limitations of pharmacological medicine in effectively treating them, has paved the way for advancements in neurostimulation approaches. The functional capabilities of various nerves in the human body, as well as the consequences of electrical stimulation of these nerves for the treatment of various illnesses, are continually being researched. As a result, new strategies and techniques for addressing and treating chronic illnesses have emerged. These procedures include spinal cord stimulation for pain relief, as well as stimulation of the vagus nerve for epilepsy and other diseases. The Market is becoming more diversified by the introduction of specialized devices and techniques to treat specific illnesses, as well as continual advancements in neurostimulation techniques.
There is a significant number of developments that are going on in this region. This region also has various developing countries, such as India and China. Governments across these countries are increasing their investment of the development of their healthcare infrastructure in order to offer enhanced treatment to their citizens. In addition, the per capita disposable income of the regional people is also increasing, due to which, they are becoming able to afford various expensive and highly advanced treatment approaches.
The increasing frequency of neurological illnesses and significant innovations in neuromodulation technology in the Asia Pacific region are driving the growth of the regional neuromodulation Market. Depression affects people of all ages and is the most commonly found neurological condition.
The China Market dominated the Asia Pacific Neuromodulation Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $305.2 million by 2028. The Japan Market is estimated to grow at a CAGR of 5.9% during (2022-2028). Additionally, The India Market is expected to showcase CAGR of 7.2% during (2022-2028).
Based on Technology, the Market is segmented into Internal and External. Based on Biomaterial, the Market is segmented into Metallic, Polymeric, and Ceramic. Based on Application, the Market is segmented into Chronic Pain, Urinary & Fecal Incontinence, Migraine, Failed Back Syndrome, Parkinson Disease, Epilepsy, Tremor, Depression, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Medtronic PLC, LivaNova PLC, Boston Scientific Corporation, Abbott Laboratories, Nevro Corporation, NeuroSigma, Inc., NeuroPace, Inc., Neuronetics, Inc., MicroTransponder Inc., and Bioventus Inc.
By Technology
By Country
Disorders of the brain, as well as the nerves that run all through the human body and the spinal cord, are referred to as neurological disorders. Some of the most common neurological ailments are acute spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ataxia, Bell's palsy, brain tumors, cerebral aneurysms, epilepsy, and seizures. Memory loss, poor mental capacity, lack of coordination, and chronic or abrupt onset of a headache are all signs of biochemical, structural, or electrical problems in the brain, spinal cord, or other nerves. Neuromodulation technology makes use of devices that stimulate or modulate brain activity to cause a change in the nervous system. When standard treatments have failed to elicit the desired reaction, they are utilized.
The rising prevalence of chronic conditions, as well as the limitations of pharmacological medicine in effectively treating them, has paved the way for advancements in neurostimulation approaches. The functional capabilities of various nerves in the human body, as well as the consequences of electrical stimulation of these nerves for the treatment of various illnesses, are continually being researched. As a result, new strategies and techniques for addressing and treating chronic illnesses have emerged. These procedures include spinal cord stimulation for pain relief, as well as stimulation of the vagus nerve for epilepsy and other diseases. The Market is becoming more diversified by the introduction of specialized devices and techniques to treat specific illnesses, as well as continual advancements in neurostimulation techniques.
There is a significant number of developments that are going on in this region. This region also has various developing countries, such as India and China. Governments across these countries are increasing their investment of the development of their healthcare infrastructure in order to offer enhanced treatment to their citizens. In addition, the per capita disposable income of the regional people is also increasing, due to which, they are becoming able to afford various expensive and highly advanced treatment approaches.
The increasing frequency of neurological illnesses and significant innovations in neuromodulation technology in the Asia Pacific region are driving the growth of the regional neuromodulation Market. Depression affects people of all ages and is the most commonly found neurological condition.
The China Market dominated the Asia Pacific Neuromodulation Market by Country in 2021, and is expected to continue to be a dominant Market till 2028; thereby, achieving a Market value of $305.2 million by 2028. The Japan Market is estimated to grow at a CAGR of 5.9% during (2022-2028). Additionally, The India Market is expected to showcase CAGR of 7.2% during (2022-2028).
Based on Technology, the Market is segmented into Internal and External. Based on Biomaterial, the Market is segmented into Metallic, Polymeric, and Ceramic. Based on Application, the Market is segmented into Chronic Pain, Urinary & Fecal Incontinence, Migraine, Failed Back Syndrome, Parkinson Disease, Epilepsy, Tremor, Depression, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The Market research report covers the analysis of key stakeholders of the Market. Key companies profiled in the report include Medtronic PLC, LivaNova PLC, Boston Scientific Corporation, Abbott Laboratories, Nevro Corporation, NeuroSigma, Inc., NeuroPace, Inc., Neuronetics, Inc., MicroTransponder Inc., and Bioventus Inc.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- Internal
- External
- Metallic
- Polymeric
- Ceramic
- Chronic Pain
- Urinary & Fecal Incontinence
- Migraine
- Failed Back Syndrome
- Parkinson Disease
- Epilepsy
- Tremor
- Depression
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- LivaNova PLC
- Boston Scientific Corporation
- Abbott Laboratories
- Nevro Corporation
- NeuroSigma, Inc.
- NeuroPace, Inc.
- Neuronetics, Inc.
- MicroTransponder Inc.
- Bioventus Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Neuromodulation Market by Technology
Chapter 5. Asia Pacific Neuromodulation Market by Biomaterial
Chapter 6. Asia Pacific Neuromodulation Market by Application
Chapter 7. Asia Pacific Neuromodulation Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Medtronic PLC
- LivaNova PLC
- Boston Scientific Corporation
- Abbott Laboratories
- Nevro Corporation
- NeuroSigma, Inc.
- NeuroPace, Inc.
- Neuronetics, Inc.
- MicroTransponder Inc.
- Bioventus Inc.
Methodology
LOADING...
